Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard

A systematic analysis of 37 post-genomic osteoarthritis (OA) studies (genomics, transcriptomics, proteomics, metabolomics) allowed to isolate 483 genes and corresponding proteins, their levels and activity disturbances are involved in the pathogenesis of the disease. These proteins can be conditionally subdivided into three groups: 1) structural proteins of connective tissue (CT); 2) proteins that support the activity of CT growth factors; 3) proteins that promote CT remodeling and degradation, as well as proteins associated with the regulation of inflammation (cellular response to tumor necrosis factor α, interleukin 1, bacterial lipopolysaccharides, NF-κB activation, etc.). It is important to note the epigenetic effects (DNA hypomethylation) associated with the pathogenesis of OA, which indicates the need for the use of vitamins group B in the therapy. Chondroprotectors (symptomatic slow-acting drugs) – chondroitin sulfate (CS) and glucosamine sulfate (GS), – in addition to reducing inflammation through inhibition of NF-κB and lipopolysaccharide receptors (Toll-receptors), also contribute to an increase in the expression of genes for structural CT proteins, CT growth factors and modulate the activity of CT remodeling and degradation proteins. These effects of CS/GS allowed to describe the complex mechanisms of the pathogenetic action of CS/GS in the treatment of OA.

show abstract

Standardised Forms of Chondroitin Sulfate as a Pathogenetic Treatment of Osteoarthritis in the Context of Post-Genomic Studies

Громова

Торшин

Лила³

et al. 2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Personalized rehabilitation program for older patients with osteoarthritis

Panikar¹,

Коршун²,

Аникин³

et al. 2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Objective: to develop a personalized rehabilitation program for improving age-related resilience (AR), antioxidant status (AOS), the quality of life and reducing pain in elderly patients with osteoarthritis (OA).Patients and methods. The program consisted of two parts. In the first part, we conducted a comparative study to assess the AR (Mahnach test), geriatric status, and AOS (amperometric flow-injection analysis) in 181 subjects in total, with coxarthrosis (n=92) and without it (n=89). The average age of patients in two groups was comparable: 72.1±1.1 and 71.9±1.1 years. Using factor analysis, we developed the personalized rehabilitation program based on the obtained data. The effectiveness of the program was evaluated in the second part of our work. We conducted an additional comparative study of changes in AR, AOS, severity of joint pain (by visual analogue scale, VAS) and quality of life (according to SF-36 questionnaire) in patients with coxarthrosis (n=114).Results and discussion. Patients with coxarthrosis had significantly lower level of AR, total antioxidant, and antiradical activity, and a higher content of Schiff bases as compared to subjects without coxarthrosis (p<0.05). The program of rehabilitation, which included a course of treatment with Chondroquard, significantly improved AR, AOS, quality of life and reduced hip pain compared to the standard OA therapy (p<0.05).Conclusion. The personalized rehabilitation program has a complex positive effect on pain, quality of life, AR and AOS in elderly patients with OA.

show abstract

Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis

Шарапова¹,

Таскина²,

Кашеварова³

et al. 2021

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Currently chondroitin sulfate (CS) is the most studied drug from the group of «chondroprotectors». The article shows the role of CS in the treatment of osteoarthritis (OA): mechanism of action, clinical efficacy and safety in patients with OA with comorbidity. Evidence for the effectiveness and safety of the use of CS has been analyzed. The place of this drug in Russian and international clinical guidelines for the management of patients with OA is discussed.In domestic practice, the parenteral form of CS is often used in patients with OA. The parenteral form of CS for intramuscular and intra-articular administration (Chondroguard®) has a number of advantages, including the rapid onset of the effect. This enables reducing the dose in a short time or completely abandon the use of non-steroidal anti-inflammatory drugs (NSAIDs), which is extremely important for patients with OA with comorbidity. Chondroguard® can be recommended for initial use in exacerbations of chronic joint and back pain in OA, including in patients with relative and absolute contraindications for NSAID therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard

Cited by 43 publications

References 14 publications

Standardised Forms of Chondroitin Sulfate as a Pathogenetic Treatment of Osteoarthritis in the Context of Post-Genomic Studies

Standardised Forms of Chondroitin Sulfate as a Pathogenetic Treatment of Osteoarthritis in the Context of Post-Genomic Studies

Personalized rehabilitation program for older patients with osteoarthritis

Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis

Contact Info

Product

Resources

About